GPCR
NASDAQ
US
Structure Therapeutics Inc. - American Depositary Shares
$53.48
▲ +$3.31
(+6.60%)
Vol 1.7M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.2B
ROE
-26.1%
D/E
0.00
Beta
-2.10
52W
$13–$95
Wall Street Consensus
23 analysts · Apr 20268
Strong Buy
13
Buy
2
Hold
0
Sell
0
Strong Sell
91.3%
Buy Rating
Price Chart
Similar Stocks
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
ALMS
Alumis Inc
$1.0B
Earnings
Beat rate: 0.0%
Next Report
May 06, 2026
EPS Estimate: $-0.36
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.36 | — | — |
| Dec 2025 | $-0.47 | $-1.22 | $-0.75 |
| Sep 2025 | $-0.36 | $-1.11 | $-0.75 |
| Jun 2025 | $-0.28 | $-1.08 | $-0.80 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$36.5M | -$46.8M | -$61.7M | -$65.7M | $33.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -21.3% | -21.3% | -21.3% | -21.3% | -26.1% | -26.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 20.48 | 20.48 | 20.48 | 20.48 | 14.15 | 14.15 |
Key Ratios
ROA (TTM)
-24.7%
P/B
1.8
EPS (TTM)
$-1.22
CF/Share
$-2.24
52W High
$94.90
52W Low
$13.22
$13.22
52-Week Range
$94.90
Financial Health
Free Cash Flow
-$65.9M
Net Debt
-$793.1M
Cash
$799.6M
Total Debt
$6.5M
As of Dec 31, 2025
How does GPCR compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
GPCR valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
—
▼
0%
below
peers
(6.7)
vs Peers
vs Industry
Overvalued
P/B ratio
1.8
▼
66%
below
peers
(5.2)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
GPCR profitability vs Pharmaceuticals peers
ROE
-26.1%
▲
0%
above
peers
(-26.1%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-1.5%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(88.9%)
vs Peers
vs Industry
Top tier
ROA
-24.7%
▼
161%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
GPCR financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(27.4)
vs Peers
vs Industry
Low debt
Current ratio
14.2
▲
307%
above
peers
(3.5)
vs Peers
vs Industry
Strong liquidity
Beta
-2.1
▼
456%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
GPCR fundamentals radar
GPCR
Peer median
Industry
GPCR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GPCR vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
STEVENS RAYMOND C
Chief Executive Officer · Mar 19
260217 shs
HALL ASHLEY
Officer · Mar 19
47706 shs
MA YINGLI
Chief Technology Officer · Mar 19
32526 shs
LIN XICHEN
Officer · Mar 19
43368 shs
YOON JUN
Chief Financial Officer · Mar 19
104085 shs
COLL CRESPO BLAS
Officer · Mar 19
75897 shs
Last 90 days
Top Holders
Top 5: 44.59%FMR, LLC
12.30%
$397.8M
Wellington Management Group…
10.05%
$325.2M
Avoro Capital Advisors LLC
9.25%
$299.3M
Janus Henderson Group PLC
7.19%
$232.4M
Deep Track Capital, Lp
5.80%
$187.7M
As of Dec 31, 2025